Drug Trial Radar · NCT00179647
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Mar 16, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,913
Actual
Start
Sep 2005
Primary completion
Dec 2008
Study completion Apr 2009
Sponsor
- Lead sponsor
- Celgene CorporationBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- Prologue Research International
- First posted
- Sep 16, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Subjects who qualify for participation will receive lenalidomide with or without dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for the indication of multiple myeloma.
Conditions
- Multiple Myeloma
Interventions
lenalidomideDrug
Lenalidomide, 5 mg to 25 mg, QD, orally, for 21 days every 28 days, with or without dexamethasone
dexamethasoneDrug
Dexamethasone, 20 mg to 40 mg, QD, orally, administered under a variety of dosing regimens
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events Summarized by System Organ Class, Preferred Term, Severity, Seriousness, and Relationship to Treatment.Time frame: Median time-on-study=18.3 weeks
- Overall Incidence of Adverse EventsTime frame: Median time-on-study=18.3 weeks
Locations
69 sites in 2 countries. Site status is shown where the registry gives one.
Mayo Clinic
Scottsdale, Arizona
Alta Bates Cancer Center
Berkeley, California
Scripps Cancer Center
La Jolla, California
Cedar Sinai Medical CenterDept of Medicine
Los Angeles, California
Kaiser Permanente Medical Group
San Diego, California
Stanford Cancer Center
Stanford, California
Kaiser Permanente Medical Center
Vallejo, California
University of ColoradoHealth Science Center
Aurora, Colorado
Rocky Mountain Cancer Center-Midtown
Denver, Colorado
Yale University School of Medicine
New Haven, Connecticut
Hematology Oncology, PC
Stamford, Connecticut
Delaware Clinical & Laboratory Physicians, PA
Newark, Delaware
University of Miami Medical School
Miami, Florida
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida
Gulf Coast Oncology
St. Petersburg, Florida
H Lee Moffitt Cancer Center
Tampa, Florida
The Palm Beach Cancer Institute
West Palm Beach, Florida
Emory University
Atlanta, Georgia
Northwestern University Med CtrDivision of Hem/Onc
Chicago, Illinois
Rush Cancer Institute
Chicago, Illinois
Indiana Univ Cancer Center Bone Marrow Transplantation Program Indiana Cancer Research Institute
Indianapolis, Indiana
University of Kansas Medical Center
Kansas City, Kansas
Wichita CCOP
Wichita, Kansas
Ochsner Clinic Foundation
New Orleans, Louisiana
University of Maryland Medical Center Greenbaum Cancer Ctr
Baltimore, Maryland
Center for Cancer And Blood Disorders
Bethesda, Maryland
Dana-Farber Cancer Institute
Boston, Massachusetts
Mayo Clinic Cancer Center
Rochester, Minnesota
Jackson Oncology Associates
Jackson, Mississippi
Siteman Cancer Center
St Louis, Missouri
Deaconess Billings Clinic
Billings, Montana
Methodist Cancer Center
Omaha, Nebraska
Nevada Cancer Center
Las Vegas, Nevada
Dartmouth Hitchcock Medical Center-Norris Cotton Cancer Center
Lebanon, New Hampshire
The Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey
SUNY Health Science Center - Brooklyn
Brooklyn, New York
North Shore Hematology/Oncology Associates, PC
East Setauket, New York
St. Vincent's Comprehensive Cancer Center
New York, New York
NY Presbyterian Hospital/Weill Medical College-Cornell University
New York, New York
SUNY Upstate Medical University
Syracuse, New York
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.